logo

Intraluminal Filament pMCAO Model

Unlike the transient middle cerebral artery occlusion (tMCAO) model, in which the filament is removed to allow reperfusion, the filament remains in place in the permanent intraluminal filament middle cerebral artery occlusion (pMCAO) model. This results in permanent blockage and a more severe, irreversible ischemic injury. Ace Therapeutics provides pMCAO models in mice, rats, and non-human primates (NHPs) to help clients study stroke mechanisms and evaluate therapeutic agents.

Unlock Insights into Stroke Research with Our Intraluminal Filament pMCAO Model Case Study

Download our intraluminal filament pMCAO model case study to see how Ace Therapeutics combines precise modeling techniques with rigorous analysis to advance stroke drug discovery. This poster showcases real experimental workflows, high-quality readouts, and translationally relevant data to help accelerate your research with confidence.

The Key Content in This Poster

  • Detailed modeling methods: Step-by-step establishment of the permanent intraluminal filament MCAO (pMCAO) model in mice.
  • Experimental workflow: From acclimatization to modeling, treatment, behavioral testing, and final analysis.
  • Comprehensive readouts: TTC staining, Neurological deficit score, and H&E histological analysis.
  • Case study data: Infarct volume measurements, behavioral outcomes, and histopathological results demonstrating model reproducibility.
  • Visual documentation: Clear images and schematics of surgical procedures and outcomes.

Download now to elevate your stroke research with Ace Therapeutics' expertly intraluminal filament pMCAO model brochure—your key to unlocking breakthroughs in ischemic stroke therapeutics!